Management of Well-Differentiated High-Grade (G3) Neuroendocrine Tumors

Mohamad Bassam Sonbol, Thorvardur R. Halfdanarson

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations


In 2017, the World Health Organization (WHO) classification for pancreatic NET was updated to include a new category of well-differentiated high-grade (Ki 67 > 20%) pancreatic tumors (NET G3), distinct from high-grade poorly differentiated neuroendocrine carcinoma (NEC). NET G3 are considered a molecularly, radiologically, and prognostically distinct entity compared to NEC and NET G1/G2. The optimal first-line management in NET G3 and sequencing therapies remains a challenge awaiting future trials taking into consideration the unique characteristics of this category. In this review, we aim to summarize the current evidence in the management of NET G3.

Original languageEnglish (US)
Article number74
JournalCurrent treatment options in oncology
Issue number9
StatePublished - Sep 1 2019


  • High-grade
  • Neuroendocrine carcinoma
  • Neuroendocrine neoplasm
  • Neuroendocrine tumor
  • PRRT

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)


Dive into the research topics of 'Management of Well-Differentiated High-Grade (G3) Neuroendocrine Tumors'. Together they form a unique fingerprint.

Cite this